An underactive thyroid is one of the most common long-term conditions treated in UK general practice, so it is a genuinely common question at Mounjaro consultations: can the two be combined safely, and does starting a GLP-1 based medicine change anything about existing thyroid treatment. The short version is that most people with a well-controlled underactive thyroid can be considered for Mounjaro (tirzepatide), but there is a specific thyroid cancer warning worth understanding properly, along with some practical points about levothyroxine timing and monitoring.
GLP-1s and the thyroid
Tirzepatide is a dual GIP and GLP-1 receptor agonist, part of the same broader medicine class as semaglutide and liraglutide. In rodent studies, medicines in this class, tirzepatide included, were associated with thyroid C-cell tumours, a rare form of thyroid cancer called medullary thyroid carcinoma (MTC). This finding has not been confirmed in humans taking these medicines, but as a precaution it appears as a class warning in the UK product information for Mounjaro and similar treatments such as Ozempic, Wegovy and Saxenda.
Because of that warning, these medicines are not given to anyone with a personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a rare inherited condition that raises the risk of that specific cancer. It is important to be clear that this is a different situation from routine underactive thyroid (hypothyroidism), which is usually caused by autoimmune thyroiditis (often referred to as Hashimoto's disease) and is not the type of thyroid disease the warning is about.
Taking Mounjaro with hypothyroidism
For the large majority of people, an existing diagnosis of hypothyroidism managed with levothyroxine is not, on its own, a reason to avoid Mounjaro. What matters clinically is the specific thyroid history: whether there has ever been a diagnosis of medullary thyroid carcinoma, a thyroid nodule that has not been properly assessed, or a family history suggesting MEN 2. A UK consultation for Mounjaro should always ask about these points before treatment starts, and it is worth mentioning any thyroid surgery, biopsy or unusual thyroid finding even if it happened years ago.
Outside of that specific exclusion, hypothyroidism itself does not change how Mounjaro works in the body, and people with well-controlled thyroid levels generally tolerate the medicine in the same way as anyone else. The two conditions are simply managed alongside one another, with routine thyroid monitoring continuing as normal.
One practical point worth knowing: an underactive thyroid that is not yet well controlled can cause tiredness, low mood, weight gain and a sluggish digestion, and some of these can overlap with the early side effects of Mounjaro, particularly nausea, reduced appetite and slower digestion. If your thyroid levels have not been checked recently, it is worth confirming they are stable before starting treatment, simply so that any new symptoms once you begin Mounjaro can be attributed correctly rather than assumed to be one thing or the other.
Levothyroxine absorption timing
Levothyroxine has narrow, fairly strict rules around how it should be taken: at a consistent time each day, on an empty stomach, and ideally 30 to 60 minutes before food, coffee or other medicines and supplements, because its absorption is sensitive to conditions in the gut. Anything that changes how the stomach and gut behave has the potential, at least in theory, to affect how well it is absorbed.
Mounjaro works partly by slowing gastric emptying, which is one of the mechanisms behind its effect on appetite. Delayed gastric emptying can, in principle, change the rate at which other oral medicines are absorbed, and UK prescribing guidance for medicines taken alongside GLP-1 and GIP receptor agonists notes this as a general point of awareness. In practice, levothyroxine absorption has not been shown to be meaningfully disrupted for most people taking it alongside tirzepatide, but the sensible approach is to keep a fixed, consistent time for levothyroxine, keep it well separated from other tablets, and mention the combination at your consultation so it can be factored into monitoring.
The usual practical advice still applies and matters more, not less, once Mounjaro is added: take levothyroxine first thing, with a full glass of water, and wait at least 30 to 60 minutes before eating, drinking coffee, or taking calcium or iron supplements, which are well known to interfere with absorption on their own. If nausea from Mounjaro makes your usual morning routine harder to stick to on certain days, it is better to keep levothyroxine at a consistent time each day where possible rather than skip or shift doses unpredictably, and to mention any pattern of missed doses at your next review.
Warnings and monitoring
A small number of symptoms deserve prompt attention while taking Mounjaro, separate from anything related to routine hypothyroidism. A new lump or swelling in the neck, hoarseness that does not settle, difficulty swallowing, or new shortness of breath should all be reported to a clinician without delay, since these could indicate a thyroid problem that needs proper assessment rather than the everyday tiredness or sluggishness sometimes associated with an underactive thyroid.
Weight itself is also relevant to monitoring. Levothyroxine dosing is often related, in part, to body weight, so a significant or fairly rapid change in weight, which is the intended effect of Mounjaro treatment, is a reasonable trigger for a thyroid function blood test (TSH) and a possible dose review. Most people already have routine thyroid checks as part of ongoing hypothyroidism management; starting Mounjaro is a sensible moment to confirm with your prescriber how often those checks should continue during treatment.
It is also worth keeping in mind that thyroid function tests can be affected by illness, other medication changes and significant weight change happening at the same time, so a single result taken shortly after starting Mounjaro is best interpreted alongside your usual pattern rather than in isolation. If a dose adjustment to your levothyroxine is needed, your prescriber will usually want to recheck levels again a few weeks later, in the same way they would after any other significant change in your health or weight.
Speak to a clinician
A Mounjaro consultation should cover your full thyroid history, not just your current levothyroxine dose. Worth having ready before you speak to a clinician: any personal or family history of thyroid cancer, particularly medullary thyroid carcinoma, or a diagnosis of MEN 2; your current thyroid medication and dose; and the date and result of your most recent thyroid function test. This lets your clinician confirm Mounjaro is appropriate for you and agree how thyroid monitoring will fit alongside your treatment.
Our wider guide to is Mounjaro safe covers the medicine's other warnings and common side effects in more depth, common side effects of GLP-1 medications explains what to expect in the first weeks of treatment, and how a weight-loss injection works explains the appetite mechanism behind the gastric emptying effect discussed above.
An underactive thyroid on its own is rarely a barrier to starting Mounjaro, but the small number of situations where it genuinely matters, particularly a history of medullary thyroid carcinoma or MEN 2, are important enough that they should always be part of the conversation before treatment begins. A thorough consultation, honest disclosure of your full thyroid history, and sensible, ongoing monitoring once treatment is under way are what keep the two conditions manageable together, rather than one complicating the other.